Emerging Therapies in Severe Eosinophilic Asthma

被引：1
|
作者：
Pang, Pee Hwee [1 ]
Brightling, Christopher E. [2 ,3 ]
机构：
[1] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, Singapore, Singapore
[2] Univ Leicester, Dept Infect Immun & Inflammat, NIHR Resp Biomed Res Unit, Inst Lung Hlth, Leicester, Leics, England
[3] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
来源：
ARCHIVOS DE BRONCONEUMOLOGIA | 2017年 / 53卷 / 05期
关键词：
DOUBLE-BLIND; INHALED CORTICOSTEROIDS; MEPOLIZUMAB; EFFICACY; PHASE-3; SAFETY; BENRALIZUMAB; MULTICENTER;
D O I：
10.1016/j.arbres.2017.01.012
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：233 / 234
页数：2
相关论文
共 50 条
  • [21] Novel and emerging therapies for asthma
    Leath, TM
    Singla, M
    Peters, SR
    DRUG DISCOVERY TODAY, 2005, 10 (23-24) : 1647 - 1655
  • [22] New and emerging therapies for asthma
    Kim, Alexander S.
    Doherty, Taylor A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 116 (01) : 14 - 17
  • [23] Eosinophilic Esophagitis Emerging Therapies and Future Perspectives
    Straumann, Alex
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (02) : 385 - +
  • [24] Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
    Menzella, Francesco
    Ruggiero, Patrizia
    Ghidoni, Giulia
    Fontana, Matteo
    Bagnasco, Diego
    Livrieri, Francesco
    Scelfo, Chiara
    Facciolongo, Nicola
    JOURNAL OF ASTHMA AND ALLERGY, 2020, 13 : 301 - 313
  • [25] . Disparate Eosinophilic Phenotypes with Age: Impact on Eligibility for AntieIL-5 Therapies in Severe Asthma
    Hekking, Pieter-Paul
    Teague, W. Gerald
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (08): : 2697 - 2698
  • [26] The impact of anti-IL5 therapies on patients with severe eosinophilic asthma: a proteomic approach
    Cameli, P.
    Vantaggiato, L.
    D'Alessandro, M.
    Bergantini, L.
    Shaba, E.
    Carleo, A.
    Di Giuseppe, F.
    Angelucci, S.
    Bini, L.
    Bargagli, E.
    Landi, C.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [27] Benralizumab (Fasenra) for Severe Eosinophilic Asthma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1541): : 33 - 35
  • [28] Mepolizumab (Nucala) for Severe Eosinophilic Asthma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1486): : 11 - 12
  • [29] Clusters of Severe Eosinophilic Asthma in a Korean Asthma Cohort
    Lee, Ji-Hyang
    An, Jin
    Won, Ha-Kyeong
    Seo, Bomi
    Kim, Jung-Hyun
    Park, So-Young
    Kim, Min-Hye
    Shin, Yoo Seob
    Jung, Jae-Woo
    Song, Woo-Jung
    Lee, Taehoon
    Kwon, Hyouk-Soo
    Lee, Jae Hyun
    Kim, Joo-Hee
    Kim, Sae-Hoon
    Chang, Yoon-Seok
    Cho, You Sook
    Nahm, Dong-Ho
    Jang, An-Soo
    Park, Jung-Won
    Yoon, Ho-Joo
    Cho, Sang-Heon
    Cho, Young-Joo
    Choi, Byoung Whui
    Moon, Hee-Bom
    Kim, Tae-Bum
    RESPIRATION, 2022, 101 (05) : 465 - 475
  • [30] Mepolizumab for the treatment of severe eosinophilic asthma
    Poulakos, Mara N.
    Cargill, Shawna M.
    Waineo, Melissa F.
    Wolford, Allen L., Jr.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 963 - 969
12345